Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice

Ramesh Gujjar, Alka Marwaha, Farah El Mazouni, John White, Karen L. White, Sharon Creason, David M. Shackleford, Jeffrey Baldwin, William N. Charman, Frederick S. Buckner, Susan Charman, Pradipsinh K. Rathod, Margaret A. Phillips

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Plasmodium falciparum causes 1-2 million deaths annually. Yet current drug therapies are compromised by resistance. We previously described potent and selective triazolopyrimidine-based inhibitors of P. falciparum dihydroorotate dehydrogenase (PfDHODH) that inhibited parasite growth in vitro; however, they showed no activity in vivo. Here we show that lack of efficacy against P. berghei in mice resulted from a combination of poor plasma exposure and reduced potency against P. berghei DHODH. For compounds containing naphthyl (DSM1) or anthracenyl (DSM2), plasma exposure was reduced upon repeated dosing. Phenyl-substituted triazolopyrimidines were synthesized leading to identification of analogs with low predicted metabolism in human liver microsomes and which showed prolonged exposure in mice. Compound 21 (DSM74), containing p-trifluoromethylphenyl, suppressed growth of P. berghei in mice after oral administration. This study provides the first proof of concept that DHODH inhibitors can suppress Plasmodium growth in vivo, validating DHODH as a new target for antimalarial chemotherapy.

Original languageEnglish (US)
Pages (from-to)1864-1872
Number of pages9
JournalJournal of Medicinal Chemistry
Volume52
Issue number7
DOIs
StatePublished - Apr 9 2009

Fingerprint

Antimalarials
Plasmodium falciparum
Growth
Drug Therapy
Plasmodium
Liver Microsomes
Oral Administration
Parasites
dihydroorotate dehydrogenase

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. / Gujjar, Ramesh; Marwaha, Alka; Mazouni, Farah El; White, John; White, Karen L.; Creason, Sharon; Shackleford, David M.; Baldwin, Jeffrey; Charman, William N.; Buckner, Frederick S.; Charman, Susan; Rathod, Pradipsinh K.; Phillips, Margaret A.

In: Journal of Medicinal Chemistry, Vol. 52, No. 7, 09.04.2009, p. 1864-1872.

Research output: Contribution to journalArticle

Gujjar, R, Marwaha, A, Mazouni, FE, White, J, White, KL, Creason, S, Shackleford, DM, Baldwin, J, Charman, WN, Buckner, FS, Charman, S, Rathod, PK & Phillips, MA 2009, 'Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice', Journal of Medicinal Chemistry, vol. 52, no. 7, pp. 1864-1872. https://doi.org/10.1021/jm801343r
Gujjar, Ramesh ; Marwaha, Alka ; Mazouni, Farah El ; White, John ; White, Karen L. ; Creason, Sharon ; Shackleford, David M. ; Baldwin, Jeffrey ; Charman, William N. ; Buckner, Frederick S. ; Charman, Susan ; Rathod, Pradipsinh K. ; Phillips, Margaret A. / Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. In: Journal of Medicinal Chemistry. 2009 ; Vol. 52, No. 7. pp. 1864-1872.
@article{772afee702df48418f0551f071cc19cf,
title = "Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice",
abstract = "Plasmodium falciparum causes 1-2 million deaths annually. Yet current drug therapies are compromised by resistance. We previously described potent and selective triazolopyrimidine-based inhibitors of P. falciparum dihydroorotate dehydrogenase (PfDHODH) that inhibited parasite growth in vitro; however, they showed no activity in vivo. Here we show that lack of efficacy against P. berghei in mice resulted from a combination of poor plasma exposure and reduced potency against P. berghei DHODH. For compounds containing naphthyl (DSM1) or anthracenyl (DSM2), plasma exposure was reduced upon repeated dosing. Phenyl-substituted triazolopyrimidines were synthesized leading to identification of analogs with low predicted metabolism in human liver microsomes and which showed prolonged exposure in mice. Compound 21 (DSM74), containing p-trifluoromethylphenyl, suppressed growth of P. berghei in mice after oral administration. This study provides the first proof of concept that DHODH inhibitors can suppress Plasmodium growth in vivo, validating DHODH as a new target for antimalarial chemotherapy.",
author = "Ramesh Gujjar and Alka Marwaha and Mazouni, {Farah El} and John White and White, {Karen L.} and Sharon Creason and Shackleford, {David M.} and Jeffrey Baldwin and Charman, {William N.} and Buckner, {Frederick S.} and Susan Charman and Rathod, {Pradipsinh K.} and Phillips, {Margaret A.}",
year = "2009",
month = "4",
day = "9",
doi = "10.1021/jm801343r",
language = "English (US)",
volume = "52",
pages = "1864--1872",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice

AU - Gujjar, Ramesh

AU - Marwaha, Alka

AU - Mazouni, Farah El

AU - White, John

AU - White, Karen L.

AU - Creason, Sharon

AU - Shackleford, David M.

AU - Baldwin, Jeffrey

AU - Charman, William N.

AU - Buckner, Frederick S.

AU - Charman, Susan

AU - Rathod, Pradipsinh K.

AU - Phillips, Margaret A.

PY - 2009/4/9

Y1 - 2009/4/9

N2 - Plasmodium falciparum causes 1-2 million deaths annually. Yet current drug therapies are compromised by resistance. We previously described potent and selective triazolopyrimidine-based inhibitors of P. falciparum dihydroorotate dehydrogenase (PfDHODH) that inhibited parasite growth in vitro; however, they showed no activity in vivo. Here we show that lack of efficacy against P. berghei in mice resulted from a combination of poor plasma exposure and reduced potency against P. berghei DHODH. For compounds containing naphthyl (DSM1) or anthracenyl (DSM2), plasma exposure was reduced upon repeated dosing. Phenyl-substituted triazolopyrimidines were synthesized leading to identification of analogs with low predicted metabolism in human liver microsomes and which showed prolonged exposure in mice. Compound 21 (DSM74), containing p-trifluoromethylphenyl, suppressed growth of P. berghei in mice after oral administration. This study provides the first proof of concept that DHODH inhibitors can suppress Plasmodium growth in vivo, validating DHODH as a new target for antimalarial chemotherapy.

AB - Plasmodium falciparum causes 1-2 million deaths annually. Yet current drug therapies are compromised by resistance. We previously described potent and selective triazolopyrimidine-based inhibitors of P. falciparum dihydroorotate dehydrogenase (PfDHODH) that inhibited parasite growth in vitro; however, they showed no activity in vivo. Here we show that lack of efficacy against P. berghei in mice resulted from a combination of poor plasma exposure and reduced potency against P. berghei DHODH. For compounds containing naphthyl (DSM1) or anthracenyl (DSM2), plasma exposure was reduced upon repeated dosing. Phenyl-substituted triazolopyrimidines were synthesized leading to identification of analogs with low predicted metabolism in human liver microsomes and which showed prolonged exposure in mice. Compound 21 (DSM74), containing p-trifluoromethylphenyl, suppressed growth of P. berghei in mice after oral administration. This study provides the first proof of concept that DHODH inhibitors can suppress Plasmodium growth in vivo, validating DHODH as a new target for antimalarial chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=64549087994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549087994&partnerID=8YFLogxK

U2 - 10.1021/jm801343r

DO - 10.1021/jm801343r

M3 - Article

VL - 52

SP - 1864

EP - 1872

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 7

ER -